South Korea approves human trial for Genexine’s coronavirus treatment drug


SEOUL (Reuters) – South Korean biotech firm Genexine Inc has received regulatory approval for a Phase I human clinical trial of its experimental coronavirus treatment drug, the Ministry of Food and Drug Safety said on Friday.

Genexine has separately said it was conducting the Phase I trial of its coronavirus vaccine on 60 participants in South Korea and plans to announce its results in October.

(Reporting by Sangmi Cha; editing by Jason Neely)


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *